Pharma Pulse: Bayer Restructures, Lilly’s Oral GLP-1 Advances, and Court Ruling Shakes Up Obesity Drug Market

This episode of Pharma Pulse covers Bayer’s $2.3 billion cost-cutting overhaul, promising Phase III results for Eli Lilly’s oral GLP-1 therapy orforglipron, and a pivotal court decision clearing the way for intensified competition in the high-growth obesity and diabetes treatment market.